Cargando…

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency

With the implementation of the new EU regulation on in vitro diagnostics (IVDR) in May 2022, notified bodies will be required to assess Companion Diagnostics (CDx). The EMA and national medicines agencies will be consulted on the performance and safety of CDx. In this paper, we report on our systema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maliepaard, Marc, Nibi, Priscilla, Nibi, Gabrièlla, Pasmooij, Anna M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120537/ https://www.ncbi.nlm.nih.gov/pubmed/35602486 http://dx.doi.org/10.3389/fmed.2022.893028

Ejemplares similares

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017
por: Maliepaard, Marc, et al.
Publicado: (2020)

The Outcome of Operated Neonates with an Isolated Congenital Diaphragmatic Hernia in a Limited Resource Scenario: A Critical Analysis
por: Hassan, Nibi, et al.
Publicado: (2021)

Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach
por: Mulder, Jorn, et al.
Publicado: (2022)

Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2023)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
por: Nicotera, Giuseppe, et al.
Publicado: (2019)

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?
por: Flynn, Robert, et al.
Publicado: (2021)

Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020
por: Maliepaard, M., et al.
Publicado: (2021)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments
por: Winstone, Julie, et al.
Publicado: (2015)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

Health horizons: Future trends and technologies from the European Medicines Agency’s horizon scanning collaborations
por: Vignali, Valentina, et al.
Publicado: (2022)

Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency
por: Chatzopoulou, Sevasti, et al.
Publicado: (2020)

European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation
por: Zoeller, R Thomas, et al.
Publicado: (2023)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Beyond this world: scientific missions of the European Space Agency
por: Calder, Nigel
Publicado: (1995)

Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators
por: Saesen, Robbe, et al.
Publicado: (2023)

The Added Value of Patient Engagement in Early Dialogue at EMA: Scientific Advice as a Case Study
por: Murphy, Aisling, et al.
Publicado: (2022)

Companion encyclopedia of marketing
Publicado: (1995)

High Level Group - Scientific Advice Mechanism - European Commission Research and Innovation - European Union
por: Laurine, Mottet
Publicado: (2017)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021
por: Naumann-Winter, Frauke, et al.
Publicado: (2022)

Regulatory agencies issue advice on use of NSAIDs for COVID-19
Publicado: (2020)

PReS13-SPK-1408: New EU scientific guidelines for JIA, SLE and GIOP from the European Medicines Agency
por: Vesely, R
Publicado: (2013)

Emergency Medicine Residents on Electronic Medical Records: Perspectives and Advice
por: Hockstein, Maxwell A, et al.
Publicado: (2019)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Towards a better use of scientific advice for developers of advanced therapies
por: Tavridou, Anna, et al.
Publicado: (2020)

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
por: Thor, Shannon, et al.
Publicado: (2023)

Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
por: Blair, Edward D., et al.
Publicado: (2012)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
por: Lenić, Ines, et al.
Publicado: (2019)

Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe
por: Akhmetov, Ildar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bi42kf7v4j9b4kk7egl9ggi9sj